Immutep Ltd ADR (IMMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immutep Ltd ADR (IMMP) has a cash flow conversion efficiency ratio of -0.284x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.12 Million) by net assets ($98.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Immutep Ltd ADR (IMMP) net asset quality to measure how much of total assets are equity-financed.
Immutep Ltd ADR - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Immutep Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Immutep Ltd ADR to evaluate the quality of earnings relative to operating cash generation.
Immutep Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immutep Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OSE Pharma SA
PA:OSE
|
-0.355x |
|
Transart Graphics Co Ltd
TW:8481
|
0.068x |
|
Pureun Mutual Savings Bank Co. Ltd
KQ:007330
|
-0.031x |
|
Panram International
TWO:8088
|
-0.193x |
|
Sam Holdings Corp
VN:SAM
|
0.114x |
|
KNH Enterprise Co Ltd
TW:9919
|
-0.038x |
|
Nova Minerals Limited
NYSE MKT:NVA
|
0.066x |
|
Jinro Distillers Co. Ltd
KQ:018120
|
0.107x |
Annual Cash Flow Conversion Efficiency for Immutep Ltd ADR (2008–2025)
The table below shows the annual cash flow conversion efficiency of Immutep Ltd ADR from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see IMMP stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $143.64 Million | $-62.05 Million | -0.432x | -135.12% |
| 2024-06-30 | $189.52 Million | $-34.82 Million | -0.184x | +30.12% |
| 2023-06-30 | $136.47 Million | $-35.88 Million | -0.263x | +18.17% |
| 2022-06-30 | $94.08 Million | $-30.23 Million | -0.321x | -33.47% |
| 2021-06-30 | $73.27 Million | $-17.64 Million | -0.241x | +26.04% |
| 2020-06-30 | $33.30 Million | $-10.84 Million | -0.326x | +48.07% |
| 2019-06-30 | $24.39 Million | $-15.29 Million | -0.627x | -170.19% |
| 2018-06-30 | $33.52 Million | $-7.78 Million | -0.232x | +27.64% |
| 2017-06-30 | $26.53 Million | $-8.51 Million | -0.321x | -0.12% |
| 2016-06-30 | $35.32 Million | $-11.31 Million | -0.320x | -1.53% |
| 2015-06-30 | $24.69 Million | $-7.79 Million | -0.315x | +49.92% |
| 2014-06-30 | $22.59 Million | $-14.23 Million | -0.630x | -14.85% |
| 2013-06-30 | $29.25 Million | $-16.04 Million | -0.548x | -6.56% |
| 2012-06-30 | $37.16 Million | $-19.12 Million | -0.515x | -190.62% |
| 2011-06-30 | $55.10 Million | $-9.76 Million | -0.177x | +54.00% |
| 2010-06-30 | $16.79 Million | $-6.46 Million | -0.385x | +62.96% |
| 2009-06-30 | $1.81 Million | $-1.88 Million | -1.039x | -76.06% |
| 2008-06-30 | $2.63 Million | $-1.55 Million | -0.590x | -- |
About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more